A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection
NCT00988325
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
65
Enrollment
INDUSTRY
Sponsor class
Conditions
Influenza
Interventions
DRUG:
Tamiflu
Sponsor
Hoffmann-La Roche